EurekAlert!

ASH 2025: Safety and efficacy data from a phase 1 study show promise of next-generation CAR-T cell therapy in patients with refractory B-cell acute lymphoblastic …

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...
ascopubs.org

Association Between Remote Monitoring and Acute Care Visits in High-Risk Patients Initiating Intravenous Antineoplastic Therapy

Traditional oncology care models have not effectively identified and managed at-risk patients to prevent acute care. A next step is to harness advances in technology to enable patients to report ...
TipRanks on MSN

PureTech’s Gallop Oncology reports positive Phase 1b trial results for LYT-200 in AML

An update from PureTech Health ( ($GB:PRTC) ) is now available. Gallop Oncology, a PureTech Health entity, announced promising results from a ...
Healio

Subset of Latino children with acute lymphoblastic leukemia may have higher relapse risk

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Among children diagnosed with acute ...
TipRanks on MSN

Race Oncology secures $3.22m for lung cancer trial

Race Oncology Ltd. ( ($AU:RAC) ) just unveiled an update. Race Oncology has secured $3.22 million through a private placement ...
The Caledonian-Record

PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk ...

The Phase 1b, open-label, dose-escalation and dose-expansion trial evaluated LYT-200 both in combination with the standard-of-care (SOC) regimen of venetoclax (VEN) and a hypomethylating agent (HMA) ...
Seeking Alpha

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1 ...

– Kura Oncology (KURA) will host a conference call on November 13, 2025, at 12:30 pm ET / 9:30 am PT – “KOMZIFTI combines compelling efficacy, a favorable safety profile, compatibility with ...